Healthcare & Biotech

As a family physician in Montreal, Dr. Sheldon Elman saw an opportunity to complement the Canadian healthcare system. He identified the personal and systemic value in treating health issues before they became medical problems, not once diagnosed. A lifelong innovator, Dr. Elman founded Medisys Health Group in 1987. Under his leadership, Medisys became Canada’s leading national private and corporate healthcare service provider. This has established Sheldon as one of Canada’s top corporate medical advisors. Sheldon served as the Chairman of Medisys until 2018 when the business was sold to Telus Health. In addition to these responsibilities, he maintains an active medical practice.

Data-driven and outcomes-focused, Carebook has partnered with a leading retail pharmacy chain and 400+ stores now leverage the Carebook platform to deliver an all-in-one pharmacy, health and wellness, and loyalty experience. Now, with a proven record in exceptional customer engagement, Carebook is taking its pharmacy solution global, and, simultaneously, is entering the sizable employee health and wellness market with our recent acquisition of Infotech Inc. Doing business as Wellness Checkpoint, InfoTech developed the first online, interactive health risk assessment and is recognized as a world-wide leader in health and productivity risk management. Currently, they serve almost one million employees with a multilingual, web-based service used by many Fortune 500 companies in over 100 countries. Information is power and engagement is longevity. Carebook aims to help businesses around the world serve the customers of today and tomorrow.

Think Research is an industry leader in delivering knowledge-based digital healthcare software solutions. The Company’s focused mission is to organize the world’s health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process, standardize care, and improve patient outcomes. For over a decade, Think Research’s cloud-based, EMR-agnostic digital tools have empowered clinicians around the world and positively impacted millions of patients across the continuum of care – including primary physician care, acute care hospitals and surgical suites as well as community and seniors care. Think Research is proud to serve as a trusted health system partner to a rapidly growing, global client base that spans five continents and more than 2,800 healthcare facilities.

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer immunotherapies based on the Company’s proprietary delivery platform (DPX). This patented technology leverages a differentiated mechanism of action that generates a targeted and durable immune activation with limited side effects. IMV’s lead candidate, Maveropepimut-S, is a T cell-activating immunotherapy that combines the utility of the platform with a novel cancer target: survivin. IMV is currently assessing Maveropepimut-S in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS). Alpha Cognition, Inc is developing a potential best-in-class, standard of care treatment, ALPHA-1062, a new acetylcholine esterase inhibitor for the treatment of mild-to-moderate Alzheimer’s disease. The company believes ALPHA-1062 may offer many advantages over current therapies that will allow it to optimize a strong position in a $5B market with no new innovation in more than a decade.

Sernova is at the forefront of the therapeutics regenerative medicine field with its research for patients suffering from T1D, hemophilia A, and thyroid disease. Sernova's Cell Pouch System could significantly improve the current standard of care for people suffering from chronic diseases by providing them with a new treatment approach that would enhance their quality of life and alleviate the burden on the system associated with the medical costs of those diseases.